Project: Research project

Project Details


DESCRIPTION: The importance of better understanding the retroviral
replication cycle in order to identify novel targets for viral control is
imperative. The avian retrovirus Rous sarcoma virus (RSV), the first virus
linked to cancer, remains the prototype oncoretrovirus. This proposal
focuses on the role of one of the major RSV structural protein, the Gag
matrix (MA) protein, in viral infection.

Little is known about the events leading to viral integration, a key step in
replication. Work from the applicant s laboratory suggests that the RSV MA
protein may play a key, undescribed, role in integration. Several mutants
within MA were identified that led to efficient production of noninfectious
particles. In one class of mutants, there was a late bock to infection,
most likely occurring immediately before integration. The first specific
aim is to examine whether MA is involved in integration. A second class of
mutants resulted in an infectivity block much earlier in infection, prior to
the initiation of reverse transcription. The second specific aim addresses
the hypothesis that MA also functions during receptor binding and fusion.
The third specific aim will characterize new MA mutants which will be
created using information from the MA structure and conserved motifs. The
fourth aim will examine how the virus interfaces with the cell during
infection and seeks to identify viral and cellular partners of MA during
early stages of infection. All of these studies are centered on the
activity of a single protein during an important part of the retroviral life
Effective start/end date7/1/986/30/20


  • National Cancer Institute: $278,655.00
  • National Cancer Institute: $279,035.00
  • National Cancer Institute: $279,401.00
  • National Cancer Institute: $278,259.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.